New drug combo shows promise for tough esophageal cancer
NCT ID NCT07403136
First seen Feb 21, 2026 · Last updated Jun 23, 2026 · Updated 19 times
Summary
This phase 2 trial tests a new drug called vebrekotuzumab, which delivers a powerful toxin directly to cancer cells that have a protein called EGFR. It is being tested alone or with an immunotherapy drug in 104 patients whose esophageal cancer has stopped responding to initial treatment. The goal is to see if this approach can shrink tumors and help patients live longer without their cancer getting worse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
vebrekotuzumab (an antibody-drug conjugate targeting EGFR) and a PD-1 inhibitor (immunotherapy)
What this could lead to
If successful, this could offer a new second-line treatment option for patients with advanced esophageal cancer, potentially slowing tumor growth and improving survival.
What could go wrong
This is an early phase 2 trial with only 104 participants, so results may not apply to all patients. The drug may cause side effects or fail to work better than current therapies.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.